Structure Therapeutics Inc.

GPCR

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001888886

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.6B
Warnings	thin data not computable: degenerate inputs, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Feb 26, 2026 262 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$20.01 2026-11-13; market equity $4.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors ("GPCRs"). These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 89.7						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	6.5%	(6.6%)	89.7	799	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 18.2					
Twelve-month failure probability	0.10%	0.08%	50.8	245	2026-09-30
Altman Z double-prime	28.10	(0.31)	1.2	743	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	24.81x	2.96x	2.7	825	2025-12-31
Growth and financing, sleeve percentile 63.3					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 3					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	not computable	2.3%			
four annual observations are required; found 3					
Net share issuance, one year	23.5%	2.4%	63.3	627	2026-02-15

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(6.2%)	(1.5%)	46
Distance from 52-week high	(78.7%)	(32.0%)	9
EBIT to enterprise value	not computable	(1.8%)	
Free cash flow yield	(5.3%)	(1.0%)	40
Book value to price	0.28	0.29	50
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	(0.23)	(0.18)	46

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$222.0M
Operating cash flow, four quarters	-$271.0M
Months of runway	9.8
Days since last periodic filing	6 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$32.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$141.2M	2025-12-31	2026-02-26	10-K	26-020562
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$222.2M	2025-12-31	2026-02-26	10-K	26-020562
3	assets	us-gaap:Assets	$1.6B	2025-12-31	2026-02-26	10-K	26-020562
4	assets	us-gaap:Assets	$903.3M	2024-12-31	2026-02-26	10-K	26-020562
5	current assets	us-gaap:AssetsCurrent	$1.6B	2025-12-31	2026-02-26	10-K	26-020562
6	current liabilities	us-gaap:LiabilitiesCurrent	$63.3M	2025-12-31	2026-02-26	10-K	26-020562
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$470.3M	2025-12-31	2026-02-26	10-K	26-020562
8	operating income	us-gaap:OperatingIncomeLoss	-$176.6M	2025-12-31	2026-02-26	10-K	26-020562
9	book equity	us-gaap:StockholdersEquity	$1.5B	2025-12-31	2026-02-26	10-K	26-020562
10	liabilities	us-gaap:Liabilities	$67.5M	2025-12-31	2026-02-26	10-K	26-020562
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.6M	2025-12-31	2026-02-26	10-K	26-020562
12	depreciation amortization	us-gaap:Depreciation	$1.3M	2025-12-31	2026-02-26	10-K	26-020562
13	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$140.7M	2025-12-31	2026-02-26	10-K	26-020562
14	income tax	us-gaap:IncomeTaxExpenseBenefit	$515,000	2025-12-31	2026-02-26	10-K	26-020562
15	current assets	us-gaap:AssetsCurrent	$891.2M	2024-12-31	2026-02-26	10-K	26-020562
16	current liabilities	us-gaap:LiabilitiesCurrent	$36.0M	2024-12-31	2026-02-26	10-K	26-020562
17	assets	us-gaap:Assets	$482.0M	2023-12-31	2025-02-27	10-K	25-001826
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	212,525,437	2026-02-15	2026-02-26	10-K	26-020562
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	172,028,543	2025-01-31	2025-02-27	10-K	25-001826

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.